About Pharos iBio

The Best Target & The Best Chemical

Overview

Pharos iBio is a new drug development company that develops treatments for rare and refractory diseases using a new drug development platform based on big data and AI technology.

About Pharos iBio
  • Based on big data analysis and artificial intelligence (AI) technology using BT&IT technology, we developed and built Chemiverse Platform, a new drug development platform, to introduce innovative new drug candidates.
  • Development of new drugs specializing in rare and refractory diseases treatment and expansion of pipelines based on proprietary technology and innovative platform
  • Expanding human and material resources and pursuing challenges beyond the limits through open innovation strategies
Company Information
  • Pharos iBio Information
  • Company
    Name

    Pharos iBio Co., Ltd.

  • Date of
    Establishment

    Apr 19, 2016

  • Business Area

    Big data and AI-based new drug development system Development of new drug specializing in treatment of rare and refractory diseases

  • Head office

    1407&1408, 38, Heungan-daero 427beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, Republic of Korea

  • Overseas
    Subsidiary

    USA, Australia

  • Number of
    Employees

    25 workers (R&D manpower : 20, 80%) As at end of March, 2022

  • Open innovation

    Yonsei University College of medicine SBSI
    Graduate School of New Drug Discovery and Development, CNU
    Seoul National University
    Kangwon National University
    Hannam University
    C&R Research
    A number of other basic R&D specialized institutions